People: Genmab A/S (GEN.CO)

GEN.CO on Copenhagen Stock Exchange

352.70DKK
19 Dec 2014
Price Change (% chg)

kr.-1.40 (-0.40%)
Prev Close
kr.354.10
Open
kr.360.00
Day's High
kr.365.00
Day's Low
kr.347.60
Volume
249,377
Avg. Vol
227,639
52-wk High
kr.365.00
52-wk Low
kr.180.10

Search Stocks

Summary

Name Age Since Current Position

Mats Pettersson

68 2013 Chairman of the Board

Jan van de Winkel

53 2010 President and Chief Executive Officer

Anders Gersel Pedersen

62 2013 Deputy Chairman of the Board

David Eatwell

53 2008 Executive Vice President and Chief Financial Officer

Anthony Pagano

36 2011 Senior Vice President, Global Finance

Paul Parren

50 2008 Senior Vice President and Scientific Director

Birgitte Stephensen

53 2010 Senior Vice President, IPR and Legal

Rachel Curtis Gravesen

45 2011 Senior Vice President, Investor Relations and Communications

Michael Bauer

49 2010 Senior Vice President, Clinical Development

Nedjad Losic

44 2010 Director, Employee Representative

Tom Vink

50 2010 Director, Employee Representative

Burton Malkiel

82 2007 Independent Director

Hans Henrik Munch-Jensen

52 2007 Independent Director

Biographies

Name Description

Mats Pettersson

Mr. Mats Pettersson has been Chairman of the Board of Directors of Genmab A/S since April 17, 2013. He has experience from international research-based biotech and pharmaceutical companies. He is Founder and Chief Executive Officer of SOBI AB. He is responsible for several transforming Business Development deals and member of various Executive management committees at Pharmacia. He is Chairman of the Board of Moberg Derma AB and Member of the Boards of to-BBB Holding NV and Photocure AS. Previously, he was Chairman of the Board of H. Lundbeck A/S and NsGene AS, and Member of the Boards of Ablynx NV, Biacore AB and Active Biotech AB. He holds a Bachelor of Science degree.

Jan van de Winkel

Prof. Jan G. J. van de Winkel, Ph.D., has been President and Chief Executive Officer of Genmab A/S since 2010. He is Co-founder of the Company and has previously served as its President, Research & Development and Chief Scientific Officer. Earlier in his carrier, he worked as Vice President and Scientific Director of Medarex Europe. Prof. van de Winkel holds a professorship in Immunotherapy at Utrecht University and is Member of the Scientific Advisory Boards of Thuja Capital Healthcare Fund and the Advisory Board of Capricorn Health-tech Fund. Additionally, he chairs the Board of Regenesance and serves as Member on the Boards of Directors of ISA Pharmaceuticals and Celdara Medical. Prof. van de Winkel holds Master of Science and Doctorate of Philosophy degrees from the University of Nijmegen.

Anders Gersel Pedersen

Dr. Anders Gersel Pedersen, M.D., Ph.D., has been Deputy Chairman of the Board of Directors of Genmab A/S since April 17, 2013. Before that, he has been Independent Chairman of the Board of Directors of the Company since 2012. He serves as Member on the Company's Compensation and Nominating & Corporate Governance Committees. He joined the Company’s Board in 2003, and was appointed Independent Deputy Chairman in 2005. Dr. Gersel Pedersen is Executive Vice President, Research & Development at H. Lundbeck A/S. During the course of his career he has held a number of Research Fellow positions at Copenhagen hospitals. He also worked for Eli Lilly for 11 years. He is Member of the European Society of Medical Oncology, the International Association for the Study of Lung Cancer, the American Society of Clinical Oncology, the Danish Society of Medical Oncology and the Danish Society of Internal Medicine. In addition, he serves on the boards of Bavarian Nordic A/S, ALK-Abello A/S and Lundbeck Cognitive Therapeutics A/S, and chairs Fonden Lundbeck International Neuroscience Foundation. Dr. Gersel Pedersen has received his Medical degree and a Doctoral degree in Neuro-oncology from Koebenhavns Universitet and a Bachelor of Science degree in Business Administration from Copenhagen Business School.

David Eatwell

Mr. David A. Eatwell has served as Executive Vice President and Chief Financial Officer of Genmab A/S since 2008. Prior to joining the Company, he was Chief Financial Officer (CFO) of Catalent Pharma Solutions, Inc., and before that, a divisional CFO of Cardinal Health, Inc. Mr. Eatwell is Member of the Association of Chartered Certified Accountants.

Anthony Pagano

Mr. Anthony Pagano has served as Senior Vice President, Global Finance at Genmab A/S since 2011. He joined the Company in 2007. Prior to joining, he was Corporate Controller and Senior Director of Business Planning at NovaDel Pharma. He started his career at KPMG LLP, reaching the position of Manager, where he provided audit and M&A consulting services. Mr. Pagano is a Certified Public Accountant and received a Bachelor of Science degree in Accounting from The College of New Jersey.

Paul Parren

Dr. Paul W. H. I. Parren, Ph.D., has served as Senior Vice President and Scientific Director at Genmab A/S since 2008. He joined the Company in 2002. Previously, he was Associate Professor in the Department of Immunology at The Scripps Research Institute in La Jolla, California. He holds Master of Science and Doctorate of Philosophy degrees from Universiteit van Amsterdam.

Birgitte Stephensen

Ms. Birgitte Stephensen has been Senior Vice President, IPR and Legal at Genmab A/S since 2010. She joined the Company in 2002. She holds a Master of Science degree from the Danish University of Pharmaceutical Sciences (currently a faculty within Koebenhavns Universitet). She has also passed the European Qualifying Examination as European Patent Attorney in 1994.

Rachel Curtis Gravesen

Ms. Rachel Curtis Gravesen has been Senior Vice President of Investor Relations and Communications at Genmab A/S since May 1, 2011. In the past she worked in investor relations and corporate communications within the healthcare sector and prior to that as a journalist at the financial news channel CNBC and the BBC in London. She had previously served for the Company having established the investor and public relations functions after the Company's IPO. Most recently, she was responsible for corporate communications at Novo Nordisk, where she specialized in critical issues management and media relations as well as working with internal communications. She holds a Master of Arts degree awarded by St John’s College, University of Cambridge and a postgraduate in Journalism from City University in London.

Michael Bauer

Dr. Michael K. Bauer, Ph.D., has served as Senior Vice President, Clinical Development at Genmab A/S since 2010. He joined the Company in 2006. Before that, he held various positions in academia, the pharmaceutical industry and the venture finance sector in Germany, New Zealand, the United States and Denmark. He holds a Master of Science degree from the Universitaet Hohenheim, Stuttgart, and a Doctorate of Philosophy degree from Georg-August-Universitaet Goettingen (University of Gottingen, Germany).

Nedjad Losic

Mr. Nedjad Losic has served as Employee Representative on the Board of Directors of Genmab A/S since 2010. He joined the Company in 2004 and serves as Director, Biometrics at Genmab’s location in Copenhagen. Prior to this, he was Managing Director of Spadille Sweden. He had also served on the Board of Directors of a number of non-industry associations. Mr. Losic holds a Master of Science degree in Mathematics from Lunds Universitet and a diploma in Management of Medical Product Innovation from the Scandinavian International Management Institute.

Tom Vink

Dr. Tom Vink, Ph.D., has been Employee Representative on the Board of Directors of Genmab A/S since 2010. He is Associate Director, Cell & Molecular Science at the Company. He joined Genmab in 2002 as Head of Molecular Biology. He holds a Master of Science degree in Biochemistry from Leiden University and a Doctorate of Philosophy degree from Universiteit Utrecht.

Burton Malkiel

Dr. Burton G. Malkiel, Ph.D., has been Independent Member of the Board of Directors of Genmab A/S since 2007. He also serves as Chairman of the Company's Audit Committee. Dr. Malkiel is the Chemical Bank Chairman’s Professor of Economics, Emeritus at Princeton University and Chief Investment Officer at Wealthfront, Inc. Previously, he was Professor of Economics, the Gordon S. Rentschler Professor of Economics and Director of the Financial Research Center at Princeton University. He served as Member of the Council of Economic Advisors under the administration of the United States President Gerald R. Ford, and as Dean at the School of Management and the William S. Beinecke Professor of Management at Yale University. In addition, he was Officer in the United States Army Finance Corps. Dr. Malkiel is Investment Committee Member at the American Philosophical Society and Maldeb Foundation. He also serves on the Board of Directors of Vanguard Group Ltd and acts as Audit Committee Chairman for Theravance, Inc. He holds a Bachelor of Arts degree in Economics from Harvard University, a Master of Business Administration degree from Harvard Graduate School of Business Administration at Harvard University, and a doctorate in Economics and Finance from Princeton University.

Hans Henrik Munch-Jensen

Mr. Hans Henrik Munch-Jensen has been Independent Member of the Board of Directors of Genmab A/S since 2007. He also serves as Chairman of the Company's Nominating & Corporate Governance Committee and as Member of the Audit Committee. Mr. Munch-Jensen is Chief Financial Officer of NordEnergie Renewables A/S. Prior to this, he held the Director position at Prospect, and from 1998 to 2007 served as Executive Vice President and Chief Financial Officer of H. Lundbeck A/S. Earlier in his carrier, he worked as a politics and finance columnist for the newspaper Dagbladet Boersen, and as Vice President of the Copenhagen Stock Exchange. Mr. Munch-Jensen is Chairman of the Board of Riddersalen Theater. In the past, he was Member of the European Federation of Pharmaceutical Industries and Associations (EFPIA), and served on various Lundbeck's boards. He holds a Master’s degree in Political Science from Aarhus Universitet.

Basic Compensation

Search Stocks